Pure and simple: understanding LNP analytics for better mRNA-based drugs
Sponsor
Ionizable lipids, the enabling technology of lipid nanoparticles (LNPs), are especially susceptible to N-oxidation affording impurities that cause loss of mRNA potency. Consequently, careful assessment of ionizable lipid purity throughout the LNP manufacturing process is of paramount importance.
In this webinar, we will explore how mRNA inactivation across 12 ionizable lipids was screened to elucidate a predictive model. Learn how lipid purity is carefully characterized using high resolution mass spectrometry coupled with a novel fragmentation technology to both detect harmful N-oxide impurities at very low abundance, and distinguish them from other oxidated impurities. We will also present key insights into ionizable lipid selection for LNP programs and demonstrate how combining LNP expertise with detailed lipid analysis streamlines process development and mitigates risk.
Join this webinar to:
- Understand how two days of careful analytics can save weeks of development time
- Discover why process-related lipid impurities are a concern in therapeutics and vaccines
- See how different ionizable lipids impact the potency of LNP therapeutics via mRNA modification
- Explore how to achieve detailed characterization of ionizable lipids through liquid chromatography mass spectrometry (LC-MS) leveraging more descriptive fragmentation
- Learn how to elucidate structures of ionizable lipid impurities, allowing differentiation of oxidative species and positioning of double bonds and saturations thereof at low levels (< 1%)
SPEAKERS
You might also like
Same-section spatial multiomics: a platform for detailed analysis of the solid tumor TME
Precision in production: optimizing monitoring and quality control for high-value plasmids
Advancing cell therapy: innovations in polymer-based encapsulation and delivery
It’s a match: cell line engineering for AAV manufacturing expands the options for therapeutic programs
